Citigroup
LXRX icon

Citigroup’s Lexicon Pharmaceuticals LXRX Stock Holding History

Citigroup’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,000
Closed -$4K – 7705
2019
Q4 		$4K Hold
1,000
– – ﹤0.01% 7454
2019
Q3 		$3K Sell
1,000
-400
-29% -$1.24K ﹤0.01% 7467
2019
Q2 		$9K Sell
1,400
-12,100
-90% -$72.4K ﹤0.01% 7339
2019
Q1 		$75K Buy
13,500
+6,300
+88% +$38.3K ﹤0.01% 6002
2018
Q4 		$48K Sell
7,200
-10,400
-59% -$84.3K ﹤0.01% 6278
2018
Q3 		$188K Sell
17,600
-1,400
-7% -$16K ﹤0.01% 5321
2018
Q2 		$228K Buy
19,000
+13,500
+245% +$138K ﹤0.01% 4925
2018
Q1 		$47K Buy
5,500
+1,900
+53% +$17.6K ﹤0.01% 6211
2017
Q4 		$36K Sell
3,600
-19,200
-84% -$199K ﹤0.01% 6394
2017
Q3 		$280K Buy
22,800
+21,500
+1,654% +$318K ﹤0.01% 4689
2017
Q2 		$21K Sell
1,300
-24,800
-95% -$384K ﹤0.01% 6248
2017
Q1 		$374K Buy
26,100
+14,400
+123% +$214K ﹤0.01% 4115
2016
Q4 		$162K Buy
11,700
+11,500
+5,750% +$185K ﹤0.01% 5457
2016
Q3 		$4K Buy
+200
New +$3.22K ﹤0.01% 6825

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup's LXRX Position: Q2 2026 in Review

Citigroup increased its Lexicon Pharmaceuticals (LXRX) stake by 5.3% in Q2 2026, buying an estimated $17.2K and bringing the position to 175,205 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #3987.

Citigroup first reported a position in LXRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.86M in Q3 2018. 148 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Citigroup held 175,205 shares of Lexicon Pharmaceuticals worth $420K as of Q2 2026.
  • Citigroup bought 8,807 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $17.2K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3987 holding.
  • Citigroup first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's Lexicon Pharmaceuticals position peaked at $2.86M in Q3 2018.
  • 148 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.